Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human cIAP-1/HIAP-2 Antibody, R&D Systems™

Goat Polyclonal Antibody has been used in 38 publications
Supplier: R&D Systems AF8181SP
This item is not returnable.
View return policy
Description
cIAP-1/HIAP-2 Polyclonal specifically detects cIAP-1/HIAP-2 in Human samples. It is validated for Western Blot, Simple Western, Immunohistochemistry, Knockout Validated.Specifications
cIAP-1/HIAP-2 | |
Polyclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
API1Hiap-2, apoptosis inhibitor 1, baculoviral IAP repeat containing 2, baculoviral IAP repeat-containing 2, baculoviral IAP repeat-containing protein 2, BIRC2, cIAP1, C-IAP1, hIAP2, HIAP-2, IAP homolog B, IAP2, IAP-2, Inhibitor of apoptosis protein 2, MIHB, MIHBHIAP2, NFR2-TRAF signalling complex protein, RING finger protein 48, RNF48hiap-2, TNFR2-TRAF-signaling complex protein 2 | |
Goat | |
Affinity Purified | |
RUO | |
329 | |
Reconstitute at 0.2 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Western Blot, Immunohistochemistry | |
LYOPH | |
Western Blot 0.5 ug/mL, Immunohistochemistry 5-15 ug/mL | |
Q13490 | |
BIRC2 | |
E. coli-derived recombinant human cIAP-1/HIAP-2 His2-Ser618 Accession # Q13490 | |
25 μg | |
Primary | |
Detects human cIAP-1/HIAP-2. Does not cross-react with recombinant human cIAP-2 or XIAP. | |
Human | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction